Glenn Liu

14.0k citations

175 papers · 8.5k indexed · 2 hit papers · h-index 46

Impact in

Pulmonary and Respiratory Medicine top 0.2%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
Cancer Research top 0.5%
- Cancer, Lipids, and Metabolism

Papers in

Pulmonary and Respiratory Medicine 123
- Prostate Cancer Treatment and Research 102
- Prostate Cancer Diagnosis and Treatment 20
- Renal cell carcinoma treatment 13
Oncology 89
- Cancer Treatment and Pharmacology 27
- Cancer Immunotherapy and Biomarkers 17

Co-authors: George Wilding Michael A. Carducci Christopher J. Sweeney Robert S. DiPaola Yu‐Hui Chen Maha Hussain Robert Dreicer Nicholas J. Vogelzang
Journals: Journal of Clinical Oncology (59 papers)Investigational New Drugs (14 papers)Clinical Cancer Research (13 papers)Clinical Genitourinary Cancer (9 papers)Cancer Chemotherapy and Pharmacology (9 papers)
Partner nations: United States Spain United Kingdom

In The Last Decade

Glenn Liu

168 papers receiving 8.4k citations

Hit Papers

align trajectories log scale

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial 2018 · 695 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Journal of Clinical Oncology
2015 New England Journal of Medicine

Peers

Countries citing papers authored by Glenn Liu

Since Specialization

Citations

This map shows the geographic impact of Glenn Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Glenn Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Glenn Liu more than expected).

Fields of papers citing papers by Glenn Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Glenn Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Glenn Liu. The network helps show where Glenn Liu may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Glenn Liu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Glenn Liu Line = papers co-authored together Glenn Liu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153). Journal of Clinical Oncology ·Christos E. Kyriakopoulos, Yu‐Hui Chen, Robert Jeraj, Fenghai Duan, Jun Luo, Emmanuel S. Antonarakis, Abhishek Tripathi, David Kosoff, Rohan Garje, Russell K. Pachynski, Rahul Atul Parikh, Andrea Harzstark, Nabil Adra, Benjamin L. Maughan, Yousef Zakharia, Paul G. Corn, Glenn Liu, Michael A. Carducci	2024	2
2	Discovery of a novel non-negative matrix factorization (NMF)-based homologous recombination deficiency (HRD) score and subsequent exploration in TALAPRO-2 (TP-2), a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology ·Karim Fizazi, Whijae Roh, Arun Azad, Xinmeng Jasmine Mu, Nobuaki Matsubara, Steven Yip, Mauminah Raina, Josep M. Piulats, Glenn Liu, Robert J. Jones, Michelle Saul, Arne Engelsberg, Jijumon Chelliserry, Douglas Laird, Neeraj Agarwal	2024	0
3	Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer Journal for ImmunoTherapy of Cancer ·Douglas G. McNeel, Hamid Emamekhoo, Jens C. Eickhoff, Christos E. Kyriakopoulos, 马利斯·施维泽Maurice, R�gen Drouin, Laura E. Johnson, Glenn Liu	2023	29
4	Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial European Urology Oncology ·Alan H. Bryce, Yu‐Hui Chen, Glenn Liu, Michael A. Carducci, 浩嗣井本, Jorge A. García, Robert Dreicer, Maha Hussain, Mario A. Eisenberger, Elizabeth R. Plimack, Nicholas J. Vogelzang, Robert S. DiPaola, Lauren C. Harshman, Christopher J. Sweeney	2020	17
5	FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab Journal for ImmunoTherapy of Cancer ·M Scarpelli, Christopher D. Zahm, Scott B. Perlman, Douglas G. McNeel, Robert Jeraj, Glenn Liu	2019	18
6	Response-to-repeatability of quantitative imaging features for longitudinal response assessment Physics in Medicine and Biology ·Xuedian D. Zhang, Stephanie A. Harmon, Tyler Bradshaw, Jens C. Eickhoff, Scott B. Perlman, Glenn Liu, Robert Jeraj	2018	6
7	A statistically optimized regional thresholding method (SORT) for bone lesion detection in ¹⁸F-NaF PET/CT imaging Physics in Medicine and Biology ·Timothy Perk, Amal Al Ghamdi, Stephanie A. Harmon, Xuedian D. Zhang, Tyler Bradshaw, Scott B. Perlman, Glenn Liu, Robert Jeraj	2018	15
8	Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel Cancer Chemotherapy and Pharmacology ·M Scarpelli, Murtuza Rampurwala, Jens C. Eickhoff, Lakeesha Carmichael, Ramona Bleiziffer, P Bergman, Jill Kolesar, Scott B. Perlman, Arisa KAKO, Gary Dukart, Chris Liang, Robert Jeraj, Glenn Liu, Justine Y. Bruce	2018	6
9	A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer Investigational New Drugs ·Christos E. Kyriakopoulos, Elisabeth I. Heath, Jens C. Eickhoff, Jill Kolesar, Edmund Luo, Thomas Moll, George Wilding, Glenn Liu	2016	9
10	Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with 18F-3′deoxy-3′fluoro-l-thymidine positron emission tomography/computed tomography Cancer Chemotherapy and Pharmacology ·Justine Y. Bruce, Liora Schwartz, Lakeesha Carmichael, Jens C. Eickhoff, Scott B. Perlman, Jill Kolesar, Ramona Bleiziffer, Robert Jeraj, Glenn Liu	2015	11
11	Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study Cancer Chemotherapy and Pharmacology ·Jaime R. Merchan, Rui Qin, Henry C. Pitot, Joel Picus, Glenn Liu, Tom R. Fitch, William J. Maples, Patrick J. Flynn, Briant Fruth, Charles Erlichman	2015	14
12	Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer Clinical Cancer Research ·Douglas G. McNeel, Jordan T. Becker, Jens C. Eickhoff, Laura E. Johnson, H. Boase, 雋輔矢野, Mary Jane Staab, Glenn Liu, George Wilding, Brian M. Olson	2014	48
13	A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors Investigational New Drugs ·Noelle K. LoConte, Albiruni R. Abdul Razak, Percy Ivy, Amyé Tevaarwerk, Rachael Leverence, Jill Kolesar, Lillian L. Siu, Sam Joseph Lubner, Daniel Mulkerin, William R. Schelman, Dustin A. Deming, Kyle D. Holen, Lakeesha Carmichael, Jens C. Eickhoff, Glenn Liu	2014	33
14	Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma Cancer Immunology Immunotherapy ·Joshua M. Lang, Amina Souyah, Marianne Wallace, Mary Jane Staab, Dorothea Horvath, George Wilding, Glenn Liu, Jens C. Eickhoff, Douglas G. McNeel, Miroslav Malkovský	2011	114
15	Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer Cancer Immunology Immunotherapy ·Douglas G. McNeel, Heath A. Smith, Jens C. Eickhoff, Joshua M. Lang, Mary Jane Staab, George Wilding, Glenn Liu	2011	78
16	A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802 Medical Oncology ·Naomi B. Haas, Xinyi Lin, Judith Manola, Michael Pins, Glenn Liu, David F. McDermott, David M. Nanus, Elisabeth I. Heath, George Wilding, Janice P. Dutcher	2011	97
17	Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer Urologic Oncology Seminars and Original Investigations ·Glenn Liu, Yu‐Hui Chen, Jill Kolesar, Wei Huang, Robert S. DiPaola, Michael Pins, Michael Carducci, Mark N. Stein, Glenn J. Bubley, George Wilding	2011	20
18	Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors Cancer Chemotherapy and Pharmacology ·Anne M. Traynor, Nikulina El, Glenn Liu, Keith T. Flaherty, Jason Clark, Steven J. Freedman, Boyd B. Scott, R Blair, Patricia A. Watson, Baiteng Zhao, Peter J. O’Dwyer, George Wilding	2010	73
19	Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862) Cancer ·Deborah Bradley, Dana E. Rathkopf, Rodney L. Dunn, Walter M. Stadler, Glenn Liu, David C. Smith, Роберто Пили, James A. Zwiebel, Howard I. Scher, Maha Hussain	2009	113
20	Phase I study of a DNA-based vaccine targeting prostatic acid phosphatase (PAP) in patients with clinical stage D0 prostate cancer Cancer Research ·Edward J. Dunphy, Mary Jane Staab, Dorothea Horvath, Jane Straus, Dona Alberti, Glenn Liu, George Wilding, Douglas G. McNeel	2007	1

About Glenn Liu

Glenn Liu is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Radiology, Nuclear Medicine and Imaging, Cancer Research and Immunology, having authored 175 papers that have together received 8.5k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (102 papers), Radiopharmaceutical Chemistry and Applications (50 papers), Cancer Treatment and Pharmacology (27 papers), Medical Imaging Techniques and Applications (20 papers), Prostate Cancer Diagnosis and Treatment (20 papers), Immunotherapy and Immune Responses (19 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Renal cell carcinoma treatment (13 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (4.9k citations), Cancer Research (1.8k citations), Oncology (2.8k citations), Radiology, Nuclear Medicine and Imaging (2.0k citations) and Immunology (905 citations). Glenn Liu has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include George Wilding, Michael A. Carducci, Christopher J. Sweeney, Robert S. DiPaola, Yu‐Hui Chen, Maha Hussain, Robert Dreicer, Nicholas J. Vogelzang, Jorge A. García and Joel Picus. Their work appears in journals such as Journal of Clinical Oncology, Investigational New Drugs, Clinical Cancer Research, Clinical Genitourinary Cancer and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact